These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Bellmunt J; Powles T; Vogelzang NJ Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651 [TBL] [Abstract][Full Text] [Related]
7. An Overview of Emerging Immunotargets of Genitourinary Tumors. Montironi R; Santoni M; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Scarpelli M Curr Drug Targets; 2016; 17(7):750-6. PubMed ID: 26648079 [TBL] [Abstract][Full Text] [Related]
14. Role of immunotherapy in kidney cancer. Nazzani S; Bazinet A; Karakiewicz PI Curr Opin Support Palliat Care; 2018 Sep; 12(3):325-333. PubMed ID: 30048250 [TBL] [Abstract][Full Text] [Related]
15. The immunotherapy revolution in genitourinary malignancies. U Gandhy S; Madan RA; Aragon-Ching JB Immunotherapy; 2020 Aug; 12(11):819-831. PubMed ID: 32594815 [TBL] [Abstract][Full Text] [Related]
16. Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578 [TBL] [Abstract][Full Text] [Related]
20. Current Landscape of Immunotherapy in Genitourinary Malignancies. Alhalabi O; Rafei H; Bilen MA; Shah AY Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]